Sobi receives FDA breakthrough designation for hemophilia drug

Swedish biotech firm Sobi has been granted the US Food and Drug Administration’s (FDA) breakthrough therapy designation for its drug candidate, efanesoctocog alfa, a potential treatment for bleeding disorder hemophilia A, the company has announced in a press release.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app